PDE4A and colorectal carcinoma: The use of PDE4 inhibitors, such as Ro20-1724 and GEBR-7b, has demonstrated a capacity to further suppress the proliferation of GNAS-mutated cells without affecting the parental cell lines, highlighting the potential therapeutic avenues that target PDE4D in GNAS-mutated CRC [115].